Evolution of the Average Target: Teva Pharmaceutical Industries Limited

Evolution of the Target Price: Teva Pharmaceutical Industries Limited

Changes in Analyst Recommendations: Teva Pharmaceutical Industries Limited

3b219971b444dc350aa682e39ec0b32.3rG_gs2q3A13ZK7C6PgRXoeW4iVqsPbc4WXDl0-_Hh4.j_mHsL_-7EgaV5yo36tQN-yhpUZY0p_liBKk7Tz4e0aSgNOzm86SRUAtxQ~30219865a7d5697e4869cfc16b2cf029
04-30 Teva Pharmaceutical Industries Positioned for Re-Rating on Growth Drivers, UBS Says MT
04-30 Truist Raises Price Target on Teva Pharmaceutical Industries to $45 From $42, Keeps Buy Rating MT
04-09 Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says MT
04-09 BofA Adjusts Price Target on Teva Pharmaceutical Industries to $42 From $38, Maintains Buy Rating MT
02-23 Medincell Rises Following Positive Decision from U.S. FDA Zonebourse
02-17 Truist Securities Adjusts Teva Pharmaceutical Industries Price Target to $42 From $38, Maintains Buy Rating MT
01-29 Truist Raises Price Target on Teva Pharmaceutical Industries to $38 From $36, Keeps Buy Rating MT
01-29 Modest Recovery for Medincell Following Sharp Decline Zonebourse
01-19 MedinCell S.A.: One to Watch Today Zonebourse
01-16 MedinCell, Biggest Gainer on the SBF 120 at Friday's Close, January 16, 2026 Zonebourse
01-07 Truist Securities Adjusts Price Target on Teva Pharmaceutical Industries to $36 From $32, Maintains Buy Rating MT
12-05 Scotiabank Initiates Teva Pharmaceutical Industries With Sector Outperform Rating, $35 Price Target MT
11-06 Truist Raises Price Target on Teva Pharmaceutical Industries to $32 From $25, Keeps Buy Rating MT
11-05 Teva Hits Highest Since 2018 as 3Q Revenue Beats Estimates MT
25-10-10 Teva Pharmaceuticals and Medincell Announce FDA Approves Expanded Indication for UZEDY®? (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder CI
25-10-09 Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says MT
25-10-09 BofA Raises Price Target on Teva Pharmaceutical Industries to $24 From $22 MT
25-05-28 Truist Securities Initiates Teva Pharmaceutical Industries at Buy With $25 Price Target MT
25-05-12 Teva Pharmaceutical Industries Shares Rise After JPMorgan Upgrades Rating MT
25-05-12 JPMorgan Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts Price Target to $23 From $21 MT
25-03-31 Teva Pharmaceutical's Upcoming Cost-Optimization Plan May Offer Significant Benefits, UBS Says MT
24-12-18 Teva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says MT
24-12-18 BofA Securities Raises Price Target on Teva Pharmaceutical Industries to $25 From $23, Keeps Buy Rating MT
24-09-09 Teva: UBS reiterates its recommendation on the stock Zonebourse
24-09-03 UBS Raises Price Target on Teva Pharmaceutical Industries to $26 From $24, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+18.66%
+9.85%
+5.49%
+11.04%
-0.21%
-0.07%
+30.43%
-8.8%
+7.27%
+19.44%
Average +9.31%
Weighted average by Cap. +8.13%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
34.81USD
Average target price
41.20USD
Spread / Average Target
+18.36%
High Price Target
50.00USD
Spread / Highest target
+43.64%
Low Price Target
33.00USD
Spread / Lowest Target
-5.20%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Truist Securities
BofA Securities
Scotiabank
JPMorgan Chase
Barclays
Piper Sandler
Goldman Sachs
Jefferies & Co.
HSBC
UBS
Evercore ISI
Bernstein
Argus
Raymond James
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
34.81USD
Average target price
41.20USD
Spread / Average Target
+18.36%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TEVA Stock
  4. Consensus Teva Pharmaceutical Industries Limited